Australia's Telix Pharma buys radioisotope production technology firm ARTMS for $42.5 M
Australia, March 6 -- based Telix Pharmaceuticals has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc., its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.
ARTMS, based in Burnaby, British Columbia (BC), Canada, is a privately held, venture-backed company, which specialises in the physics, chemistry and materials science of cyclotron-produced radionuclides. A spin-out company from the internationally renowned TRIUMF, Canada's particle accelerator centre, ARTMS is a commercial-stage company: its technology is used by the major manufacturing networks to optimise production of a range of medical...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.